<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="retraction" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2024.1480131</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Retraction</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Retraction: Corrigendum: Natural killer cell-derived exosomal miR-3607-3p inhibits pancreatic cancer progression by targeting IL-26</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<collab>Frontiers Editorial Office</collab>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/228891"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
</contrib-group>
<author-notes>
<fn fn-type="edited-by">
<p>Approved by: Luigi Daniele Notarangelo, National Institute of Allergy and Infectious Diseases (NIH), United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Frontiers Editorial Office, <email xlink:href="mailto:research.integrity@frontiersin.org">research.integrity@frontiersin.org</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>19</day>
<month>08</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1480131</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>08</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>08</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Frontiers Editorial Office</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Frontiers Editorial Office</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<related-article id="RA1" related-article-type="retracted-article" xlink:href="10.3389/fimmu.2020.00277" ext-link-type="doi">A Retraction of the Corrigendum Article <article-title>Corrigendum: Natural killer cell-derived exosomal miR-3607-3p inhibits pancreatic cancer progression by targeting IL-26</article-title> By Sun H, Shi K, Qi K, Kong H, Zhang J, Dai S, Ye W, Deng T, He Q and Zhou M (2020). <italic>Front. Immunol.</italic> 11:277. doi:&#xa0;<object-id>10.3389/fimmu.2020.00277</object-id>
</related-article>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="7"/>
<word-count count="59"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Cancer Immunity and Immunotherapy</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers&#x2019; policies.</p>
<p>This retraction was approved by the Chief Editors of Frontiers in Immunology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.</p>
</body>
</article>